RxDoctor Payments Data

Shaukat Ali, MD

Interventional Cardiology · Fresno, CANPI 1154521540

Payments from drug & device makers

$8,283in general payments, 2019–2025

Across 246 payments — averaging $33.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Amgen$2K
  • Cardiovascular Systems Inc.$580
  • Medtronic$515
  • Edwards Lifesciences$430
  • Novartis$215
  • plus $951 from 12 others

What the payments were for

  • Travel & lodging$1,92923%
  • Food & beverage$6,35377%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,283 in reported general payments places this provider in the 45th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$1,988,504
Medicare patients
1,655
Services billed
10,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban376$493,833
Repatha SureclickEvolocumab105$106,878
XareltoRivaroxaban90$95,837
EntrestoSacubitril/Valsartan68$86,030
Metoprolol Succinate1,320$20,405
OzempicSemaglutide22$20,366
BrilintaTicagrelor13$15,546
NexlizetBempedoic Acid/Ezetimibe16$14,599
VascepaIcosapent Ethyl27$11,973
JardianceEmpagliflozin11$11,942
ClopidogrelClopidogrel Bisulfate494$7,189
Atorvastatin Calcium601$6,840
Ranolazine ErRanolazine58$6,776
Midodrine Hcl30$6,397
EdarbyclorAzilsartan Med/Chlorthalidone12$6,096

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$128$493,833376 claims
Johnson & JohnsonXarelto$50$95,83790 claims
NovartisEntresto$215$86,03068 claims
AstraZenecaBrilinta$144$15,54613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →